{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:22:07Z","timestamp":1780730527193,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_00002\/7"],"award-info":[{"award-number":["MC_UU_00002\/7"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Beta-blocker (BB) and calcium channel blocker (CCB) antihypertensive drugs are commonly used in pregnancy. However, data on their relative impact on maternal and foetal outcomes are limited. We leveraged genetic variants mimicking BB and CCB antihypertensive drugs to investigate their effects on risk of pre-eclampsia, gestational diabetes and birthweight using the Mendelian randomization paradigm.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Genetic association estimates for systolic blood pressure (SBP) were extracted from summary data of a genome-wide association study (GWAS) on 757,601 participants. Uncorrelated single-nucleotide polymorphisms (SNPs) associated with SBP (<jats:italic>p<\/jats:italic>\u2009&lt;\u20095\u2009\u00d7\u200910<jats:sup>\u22128<\/jats:sup>) in BB and CCB drug target gene regions were selected as proxies for drug target perturbation. Genetic association estimates for the outcomes were extracted from GWASs on 4743 cases and 136,325 controls (women without a hypertensive disorder in pregnancy) for pre-eclampsia or eclampsia, 7676 cases and 130,424 controls (women without any pregnancy-related morbidity) for gestational diabetes, and 155,202 women (who have given birth at least once) for birthweight of the first child. All studies were in European ancestry populations. Mendelian randomization estimates were generated using the two-sample inverse-variance weighted model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Although not reaching the conventional threshold for statistical significance, genetically-proxied BB was associated with reduced risk of pre-eclampsia (OR per 10\u00a0mmHg SBP reduction 0.27, 95%CI 0.06\u20131.19, <jats:italic>p<\/jats:italic>\u2009=\u20090.08) and increased risk of gestational diabetes (OR per 10\u00a0mmHg SBP reduction 2.01, 95%CI 0.91\u20134.42, <jats:italic>p<\/jats:italic>\u2009=\u20090.08), and significantly associated with lower birthweight of first child (beta per 10\u00a0mmHg SBP reduction\u2009\u2212\u20090.27, 95%CI\u2009\u2212\u20090.39 to\u2009\u2212\u20090.15, <jats:italic>p<\/jats:italic>\u2009=\u20091.90\u2009\u00d7\u200910<jats:sup>\u22125<\/jats:sup>). Genetically-proxied CCB was associated with reduced risk of pre-eclampsia and eclampsia (OR 0.62, 95%CI 0.43\u20130.89, <jats:italic>p<\/jats:italic>\u2009=\u20099.33\u2009\u00d7\u200910<jats:sup>\u22123<\/jats:sup>), and was not associated with gestational diabetes (OR 1.05, 95% CI 0.76\u20131.45, <jats:italic>p<\/jats:italic>\u2009=\u20090.76) or changes in birthweight of first child (beta per 10\u00a0mmHg SBP reduction 0.02, 95%CI\u2009\u2212\u20090.04\u20130.07, <jats:italic>p<\/jats:italic>\u2009=\u20090.54).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>While BB and CCB antihypertensive drugs may both be efficacious for lowering blood pressure in pregnancy, this genetic evidence suggests that BB use may lower birthweight. Conversely, CCB use may reduce risk of pre-eclampsia and eclampsia without impacting gestational diabetes risk or birthweight. These data support further study on the effects of BBs on birthweight.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-022-02483-1","type":"journal-article","created":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:02:53Z","timestamp":1662422573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Safety of beta-blocker and calcium channel blocker antihypertensive drugs in pregnancy: a Mendelian randomization study"],"prefix":"10.1186","volume":"20","author":[{"given":"Maddalena","family":"Ardissino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A. W.","family":"Slob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skanda","family":"Rajasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohin K.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Woolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Girling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu Siong","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7312-7078","authenticated-orcid":false,"given":"Dipender","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,6]]},"reference":[{"key":"2483_CR1","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1016\/j.jacc.2020.03.028","volume":"75","author":"VD Garovic","year":"2020","unstructured":"Garovic VD, White WM, Vaughan L, Saiki M, Parashuram S, Garcia-Valencia O, et al. Incidence and long-term outcomes of hypertensive disorders of pregnancy. J Am Coll Cardiol. 2020;75:2323\u201334.","journal-title":"J Am Coll Cardiol"},{"key":"2483_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preghy.2021.02.005","volume":"24 February","author":"L Corrigan","year":"2021","unstructured":"Corrigan L, O\u2019Farrell A, Moran P, Daly D. Hypertension in pregnancy: Prevalence, risk factors and outcomes for women birthing in Ireland. Pregnancy Hypertens. 2021;24 February:1\u20136.","journal-title":"Pregnancy Hypertens"},{"key":"2483_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/aje\/155.3.203","volume":"155","author":"X Xiong","year":"2002","unstructured":"Xiong X. Impact of preeclampsia and gestational hypertension on birth weight by gestational age. Am J Epidemiol. 2002;155:203\u20139.","journal-title":"Am J Epidemiol"},{"key":"2483_CR4","doi-asserted-by":"publisher","unstructured":"Tita AT, Szychowski JM, Boggess K, Dugoff L, Sibai B, Lawrence K, et al. Treatment for mild chronic hypertension during pregnancy. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2201295.","DOI":"10.1056\/NEJMoa2201295"},{"key":"2483_CR5","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/jch.13397","volume":"20","author":"L Duan","year":"2018","unstructured":"Duan L, Ng A, Chen W, Spencer HT, Lee M-S. Beta-blocker subtypes and risk of low birth weight in newborns. J Clin Hypertens. 2018;20:1603\u20139.","journal-title":"J Clin Hypertens"},{"key":"2483_CR6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1056\/NEJMoa1404595","volume":"372","author":"LA Magee","year":"2015","unstructured":"Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372:407\u201317.","journal-title":"N Engl J Med"},{"key":"2483_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0140-6736(98)08049-0","volume":"355","author":"P von Dadelszen","year":"2000","unstructured":"von Dadelszen P, Ornstein M, Bull S, Logan A, Koren G, Magee L. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355:87\u201392.","journal-title":"Lancet"},{"key":"2483_CR8","unstructured":"NICE 2019. Hypertension in pregnancy: diagnosis and management [NG 133]. National Institute for Health and Care Excellence (NICE); https:\/\/www.nice.org.uk\/guidance\/ng133. 2019; https:\/\/www.nice.org.uk\/guidance\/ng133. http:\/\/www.nice.org.uk\/guidance\/cg107%5Cn;https:\/\/www.dovepress.com\/getfile.php?fileID=7818%5Cn; http:\/\/www.ijgo.org\/article\/S0020-7292(02)80002-9\/abstract. Accessed 10 Mar 2022. Last Accessed on 2022\u201303\u201310."},{"key":"2483_CR9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1161\/HYPERTENSIONAHA.121.18415","volume":"79","author":"JN Bone","year":"2022","unstructured":"Bone JN, Sandhu A, Abalos ED, Khalil A, Singer J, Prasad S, et al. Oral antihypertensives for nonsevere pregnancy hypertension: systematic review, network meta- and trial sequential analyses. Hypertension. 2022;79:614\u201328.","journal-title":"Hypertension"},{"key":"2483_CR10","first-page":"CD002252","volume":"10","author":"E Abalos","year":"2018","unstructured":"Abalos E, Duley L, Steyn DW, Gialdini C. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane database Syst Rev. 2018;10:CD002252.","journal-title":"Cochrane database Syst Rev"},{"key":"2483_CR11","doi-asserted-by":"publisher","first-page":"16","DOI":"10.12688\/wellcomeopenres.16544.1","volume":"6","author":"D Gill","year":"2021","unstructured":"Gill D, Georgakis MK, Walker VM, Schmidt AF, Gkatzionis A, Freitag DF, et al. Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Res. 2021;6:16.","journal-title":"Wellcome Open Res"},{"key":"2483_CR12","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1097\/AOG.0000000000001145","volume":"126","author":"Committee on Ethics","year":"2015","unstructured":"Committee on Ethics. Committee opinion no. 646 summary: ethical considerations for including women as research participants. Obstet Gynecol. 2015;126:1127\u20138.","journal-title":"Obstet Gynecol"},{"key":"2483_CR13","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(21)01920-6","volume":"398","author":"M Nazarzadeh","year":"2021","unstructured":"Nazarzadeh M, Bidel Z, Canoy D, Copland E, Wamil M, Majert J, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet. 2021;398:1803\u201310.","journal-title":"Lancet"},{"key":"2483_CR14","doi-asserted-by":"publisher","unstructured":"Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018. https:\/\/doi.org\/10.1038\/s41588-018-0205-x.","DOI":"10.1038\/s41588-018-0205-x"},{"key":"2483_CR15","unstructured":"FinnGen. FinnGen consortium, R6 Available https\/\/www.finngen.fi\/en\/access_results Accessed 04 April 2022."},{"key":"2483_CR16","unstructured":"Neale lab: UK Biobank GWAS Results. Neale lab, available http\/\/www.nealelab.is\/uk-biobank Accessed 04 April 2022."},{"key":"2483_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/EDE.0000000000000559","volume":"28","author":"S Burgess","year":"2017","unstructured":"Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust causal inference from mendelian randomization analyses with multiple genetic variants. Epidemiology. 2017;28:30\u201342.","journal-title":"Epidemiology"},{"key":"2483_CR18","doi-asserted-by":"publisher","first-page":"e34408","DOI":"10.7554\/eLife.34408","volume":"7","author":"G Hemani","year":"2018","unstructured":"Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.","journal-title":"Elife"},{"key":"2483_CR19","unstructured":"R Core Team. 2022. R: A language and environment for statistical computing. R Found Stat Comput Vienna, Austria. https:\/\/www.R-project.org\/."},{"key":"2483_CR20","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/sim.7221","volume":"36","author":"J Bowden","year":"2017","unstructured":"Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017;36:1783\u2013802.","journal-title":"Stat Med"},{"issue":"5","key":"2483_CR21","doi-asserted-by":"publisher","first-page":"e1004383","DOI":"10.1371\/journal.pgen.1004383","volume":"10","author":"C Giambartolomei","year":"2014","unstructured":"Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 2014;10(5):e1004383.","journal-title":"PLoS Genet"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02483-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02483-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02483-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:03:06Z","timestamp":1662422586000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02483-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,6]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2483"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02483-1","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,6]]},"assertion":[{"value":"22 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DG is employed part-time by Novo Nordisk. All other co-authors have no relevant disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"288"}}